R&D and innovation are the driving force of growth of BrightGene. Our main developing directions are: research, development and production of innovative drugs and high-end generic drugs. The innovative drugs include antibody - drug conjugate (ADC) and small molecule drug conjugates (SMDC); high-end generic drugs include the difficult-to-synthesis generic drugs, semi-synthetic fermentation products, biosimilars and special drug delivery systems
Innovative Drugs
Generic Drugs
Our Mission